Logo

Roche's Tecentriq + Avastin Receive FDA's Breakthrough Designation as 1L Treatment for Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Share this

Roche's Tecentriq + Avastin Receive FDA's Breakthrough Designation as 1L Treatment for Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Shots:

  • The FDA’s BT designation is based on P-Ib (NCT02715531) study assessing Tecentriq (1200mg) + Avastin (15 mg/kg) in 23 patients with advanced or metastatic first-line HCC
  • The P-Ib study results: median follow-up of 10.3 mos. as per RECIST v1.1 (65%); response rate (61%); PFS- DOR- TTP- & OS not reached follow up of 10.3 mos.; no new safety signals
  • Tecentriq (atezolizumab) + Avastin (bevacizumab) is a combination therapy- Tecentriq inhibit VEGF to restores anti-cancer immunity & Avastin shows anti-angiogenic effects enhancing the effect of Tecentriq

Ref: Roche | Image: Roche

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions